These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 23277196)

  • 1. Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
    Lamontanara AJ; Gencer EB; Kuzyk O; Hantschel O
    Biochim Biophys Acta; 2013 Jul; 1834(7):1449-59. PubMed ID: 23277196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming kinase resistance in chronic myeloid leukemia.
    Lee F; Fandi A; Voi M
    Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
    O'Hare T; Eide CA; Deininger MW
    Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
    Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
    Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia.
    O'Hare T; Eide CA; Deininger MW
    Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S120-30. PubMed ID: 17382021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
    von Bubnoff N; Manley PW; Mestan J; Sanger J; Peschel C; Duyster J
    Blood; 2006 Aug; 108(4):1328-33. PubMed ID: 16614241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
    Ma L; Shan Y; Bai R; Xue L; Eide CA; Ou J; Zhu LJ; Hutchinson L; Cerny J; Khoury HJ; Sheng Z; Druker BJ; Li S; Green MR
    Sci Transl Med; 2014 Sep; 6(252):252ra121. PubMed ID: 25186176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
    Weisberg E; Manley PW; Cowan-Jacob SW; Hochhaus A; Griffin JD
    Nat Rev Cancer; 2007 May; 7(5):345-56. PubMed ID: 17457302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance to BCR-ABL kinase inhibitors.
    Diamond JM; Melo JV
    Leuk Lymphoma; 2011 Feb; 52 Suppl 1():12-22. PubMed ID: 21299456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
    Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
    Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
    [No Abstract]   [Full Text] [Related]  

  • 15. Treating imatinib-resistant leukemia: the next generation targeted therapies.
    Burgess MR; Sawyers CL
    ScientificWorldJournal; 2006 Aug; 6():918-30. PubMed ID: 16906325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.
    O'Hare T; Eide CA; Deininger MW
    Blood; 2007 Oct; 110(7):2242-9. PubMed ID: 17496200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
    von Bubnoff N; Veach DR; van der Kuip H; Aulitzky WE; Sänger J; Seipel P; Bornmann WG; Peschel C; Clarkson B; Duyster J
    Blood; 2005 Feb; 105(4):1652-9. PubMed ID: 15459011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
    Bixby D; Talpaz M
    Hematology Am Soc Hematol Educ Program; 2009; ():461-76. PubMed ID: 20008232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
    Gniot M; Wasilewska EM; Lewandowski K
    Int J Lab Hematol; 2012 Dec; 34(6):e3-6. PubMed ID: 25998099
    [No Abstract]   [Full Text] [Related]  

  • 20. Overcoming resistance in chronic myelogenous leukemia.
    Cooper S; Giles FJ; Savona MR
    Leuk Lymphoma; 2009 Nov; 50(11):1785-93. PubMed ID: 19883308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.